Drug details:
Molecular formula: C₁₈H₁₈ClN₅O₃S

Standard name: N-[(5-chloropyridin-2-yl)carbamothioyl]-3-nitro-4-piperidin-1-ylbenzamide

Synonyms:

N-((5-Chloropyridin-2-yl)carbamothioyl)-3-nitro-4-(piperidin-1-yl)benzamide N-[(5-chloropyridin-2-yl)carbamothioyl]-3-nitro-4-piperidin-1-ylbenzamide N-[(5-chloropyridin-2-yl)carbamothioyl]-3-nitro-4-(piperidin-1-yl)benzamide 3-(5-chloropyridin-2-yl)-1-[3-nitro-4-(piperidin-1-yl)benzoyl]thiourea 1-(5-CHLOROPYRIDIN-2-YL)-3-[3-NITRO-4-(PIPERIDIN-1-YL)BENZOYL]THIOUREA

Curated SMILES: C1CCN(CC1)C2=C(C=C(C=C2)C(=O)NC(=S)NC3=NC=C(C=C3)Cl)[N+](=O)[O-]

Evidence for compound's anti-virulence activity:

Staphylococcus
Related VFcategory: Regulation; Biofilm
Target: GraR
Drug effect: Targets GraR, a regulator of the cell-envelope stress response; inhibits biofilm formation and abrogates intracellular survival in macrophages.
Max phase: Preclinical (in vivo)
Publication:
El-Halfawy OM, et al., 2020. Discovery of an antivirulence compound that reverses β-lactam resistance in MRSA. Nat Chem Biol 16(2):143-149.